They suggested that polynucleotide kinase 3′-phosphatase (PNKP) is a critical mediator of this aberrant repair process, showing increased association with mutant H3.3; hence, targeting PNKP is a promising therapeutic strategy for gliomas and other cancers with these mutations (Figure 4). The gene discussed is PNKP; the disease is glioma.